Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A small pilot clinical study at the National Eye Institute (NEI) suggests that the drug nitisinone increases melanin production in some people with oculocutaneous albinism type 1B (OCA-1B), a rare genetic disease that causes pale skin and hair and poor vi
A new form of therapy may halt or even reverse a form of progressive vision loss, spinocerebellar ataxia type 7 (SCA7). This new therapy has the potential to treat neurogenetic diseases effectively and with far fewer side effects than other medications.
Scientists funded by the National Eye Institute (NEI) report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP).
National Eye Institute (NEI) Postdoctoral Fellow Aman George, Ph.D., has received a $65,000 grant from the Knights Templar Eye Foundation to identify new drug treatments for vision impairment in children with a type of albinism.